Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Information for site staff

Every COVID-19 patient in the UK may be invited to participate in the RECOVERY Trial. Randomisation includes the following arms: usual care alone; azithromycin; convalescent plasma; REGN-COV2 monoclonal antibodies; and aspirin. There is a second randomisation for participants who deteriorate between tocilizumab and control. The trial is designed to have the least possible impact on NHS staff. You will find Frequently Asked Questions on the site set-up page.

See Update Alert on this page for update details.  

RECOVERY-website_icons_site-set-up-2 (003).png

RECOVERY-website_icons.png

RECOVERY-website_icons_SITE-TEAMS.png

RECOVERY-website_icons_training.png

RECOVERY-website_icon_randomisation.png

RECOVERY-website_icons_follow-up (003).png

update alerts

20 november 2020

Substantial amendment 11 has been submitted to add colchicine to the trial protocol. The relevant documents are on the regulatory documents page. Please note that an updated version of the REGN-COV2 Investigators’ Brochure is included and has the same password as before. Please contact recoverytrial@ndph.ox.ac.uk if you need this password. 

We are also removing azithromycin from the protocol as we have recruited a sufficient number of participants. Participants may still be recruited into this comparison as protocol V10.1 remains active. Please note that we have approval from NHS England (and devolved nations) to use NHS stocks of colchicine (and aspirin) in the RECOVERY trial.

30 October 2020

Statement on Regeneron’s pause in recruitment to a REGN-COV2 antibody cocktail trial